文献速递前列腺癌

17基因基因组前列腺评分作为主动监测男性不良病理的预测因子

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
PubMed 文献 · J Urol · 2019-09-06

研究纳入加州大学旧金山分校215例接受主动监测、后行根治性前列腺切除术的前列腺癌患者,评估GPS(Oncotype Dx基因组前列腺评分)与不良病理及生化复发的关系。多因素分析显示,GPS每升高5单位,不良病理风险增加(HR 1.16,95%CI 1.06-1.26,p<0.01),生化复发风险增加(HR 1.10,95%CI 1.00-1.21,p=0.04)。

要点

  • 在主动监测后行根治性前列腺切除术的患者中,较高的GPS与不良病理风险增加相关。
  • GPS每升高5单位,不良病理风险HR为1.16(95%CI 1.06-1.26,p<0.01)。
  • GPS每升高5单位,生化复发风险HR为1.10(95%CI 1.00-1.21,p=0.04)。

核心结论

  • 在主动监测一段时间后行根治性前列腺切除术的患者中,与立即行前列腺切除术的患者一样,较高的GPS与不良病理风险增加相关。
  • GPS还与这类患者根治性前列腺切除术后的生化复发相关。

研究设计与样本

  • 研究纳入加州大学旧金山分校所有接受主动监测、Gleason评分3+3或低体积(阳性穿刺针数≤33%)Gleason评分3+4、在诊断或确认活检时行GPS检测、临床分期T1/T2、前列腺特异性抗原<20且临床CAPRA评分<6的前列腺癌患者。
  • 共纳入215例男性,其中179例(83%)按CAPRA评分为低危,36例(17%)为中危。
  • GPS中位数为26.4(IQR 18.8-34.6)。
  • 主要结局为不良病理,定义为Gleason评分4+3或更高、分期pT3a或更高、或pN1。
  • 次要结局为生化复发,定义为根治性前列腺切除术后连续2次前列腺特异性抗原测量值大于0.05 ng/ml。

主要发现

  • 多因素分析显示,较高的GPS与延迟根治性前列腺切除术时不良病理风险增加相关(每5单位HR 1.16,95%CI 1.06-1.26,p<0.01)。
  • 较高的GPS还与生化复发风险增加相关(每5单位HR 1.10,95%CI 1.00-1.21,p=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The GPS (Oncotype Dx® Genomic Prostate Score) test is a RNA expression assay which can be performed on prostate biopsies. We sought to determine whether the GPS was associated with an increased risk of adverse pathology findings in men enrolled on active surveillance who later underwent radical prostatectomy. MATERIALS AND METHODS: We identified all patients on active surveillance at University of California-San Francisco who had Gleason score 3 + 3 or low volume (33% or fewer positive cores) Gleason score 3 + 4 prostate cancer, GPS testing at diagnostic or confirmatory biopsy, clinical stage T1/T2, prostate specific antigen less than 20 and a clinical CAPRA (Cancer of the Prostate Risk Assessment) score less than 6. The primary outcome was adverse pathology, defined as Gleason score 4 + 3 or greater, stage pT3a or greater, or pN1. The secondary outcome was biochemical recurrence, defined as 2 consecutive prostate specific antigen measurements greater than 0.05 ng/ml following radical prostatectomy. RESULTS: Of the 215 men 179 (83%) were at low risk and 36 (17%) were at intermediate risk by CAPRA scoring. The median GPS was 26.4 (IQR 18.8-34.6). On multivariate analysis a higher GPS was associated with an increased risk of adverse pathology at delayed radical prostatectomy (HR/5 units 1.16, 95% CI 1.06-1.26, p <0.01). A higher GPS was also associated with an increased risk of biochemical recurrence (HR/5 units 1.10, 95% CI 1.00-1.21, p=0.04). CONCLUSIONS: In patients who undergo radical prostatectomy after a period on active surveillance, as in those who undergo immediate prostatectomy, a higher GPS is associated with an increased risk of adverse pathology. The GPS is also associated with biochemical recurrence following radical prostatectomy in such patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kornberg Z, Cooperberg MR, Cowan JE, et al. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019. PMID: 31026214. doi:10.1097/JU.0000000000000290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。